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ABSTRACT
Introduction: The objective of this non-inter-
ventional study was to investigate the long-
term safety and effectiveness of certolizumab
pegol (CZP) in patients with rheumatoid
arthritis (RA) in the UK and Ireland.
Methods: Patients were prescribed CZP at their
physicians’ discretion and followed during
routine clinical practice for up to 88 weeks.
DAS28(ESR) response (defined as at least a 1.2-
point reduction from baseline) was measured in
the full analysis set (FAS) at week 12, and
patients were categorized by week 12 responder
status in all subsequent analyses. The primary
outcome was DAS28(ESR) response at week 78.
Secondary outcomes included change from
baseline in DAS28(ESR), HAQ-DI, and RADAI
scores at week 78, and EULAR response at week
78. Adverse drug reactions (ADRs) were recor-
ded for all patients who received at least one
dose of CZP.
Results: A total of 149 patients were enrolled,
of whom 111 (74.5%) formed the FAS. At week
12, 80 patients (72.1%) were DAS28(ESR)
responders and 31 (27.9%) non-responders.
Compared to non-responders, a greater pro-
portion of week 12 responders had a
DAS28(ESR) response at week 78 (43.8% versus
22.6%). Improvements in DAS28(ESR), HAQ-DI,
and RADAI scores were also greater on average
among week 12 responders, as was the propor-
tion of patients meeting EULAR criteria. Over-
all, 9 patients (6.1%) experienced 13 ADRs
during the study.
Conclusion: These data demonstrate the safety
and effectiveness of CZP in adult patients with
RA treated during routine clinical practice in
the UK and Ireland.
Trial Registration: ClinicalTrials.gov identifier,
NCT01288287.
Funding: UCB Pharma.
Enhanced digital features To view enhanced digital
features for this article go to https://doi.org/10.6084/
m9.figshare.6839597.
Electronic supplementary material The online
version of this article (https://doi.org/10.1007/s12325-
018-0758-1) contains supplementary material, which is
available to authorized users.
N. Kumar (&)
University Hospital of North Durham, Durham, UK
e-mail: Namita.Kumar@hee.nhs.uk
S. Naz
North Manchester General Hospital, Manchester,
UK
M. Quinn
York Hospital, York, UK
J. Ryan
Cork University Hospital, Cork, Ireland
T. Kumke
UCB Pharma, Monheim, Germany
T. Sheeran
Cannock Chase Hospital, Cannock, UK
Adv Ther (2018) 35:1426–1437
https://doi.org/10.1007/s12325-018-0758-1
Keywords: Anti-TNF; Arthritis; Certolizumab
pegol; DAS28; DMARDs (biologic);
Rheumatoid arthritis; Rheumatology
INTRODUCTION
Although the treatment options available for
rheumatoid arthritis (RA) have expanded con-
siderably over the past decade, patients who do
not receive adequate treatment in the early
stages of disease may experience progressive
joint damage and substantial functional
impairment [1, 2].
Certolizumab pegol (CZP) is an Fc-free,
PEGylated anti-tumor necrosis factor (anti-TNF)
that has demonstrated rapid efficacy and an
acceptable safety profile in clinical studies of
patients with RA [3–7]. Moreover, there is evi-
dence that early response to CZP may be sus-
tained in the long term, at least in a trial
context [8, 9]. For example, patients treated
with CZP in the RAPID 1 study experienced
improvements in clinical and patient-reported
outcomes after 1 week, which were maintained
over 1 year [7]. Similar outcomes have been
observed in a German non-interventional study
(NCT01069419) [10], in which patients treated
with CZP during routine clinical practice
achieved a rapid reduction of disease activity by
week 12, which was maintained to week 52.
However, there are currently limited real-world
data describing these outcomes in the UK and
Ireland.
Here we report data from a long-term, non-
interventional study designed to investigate the
safety and effectiveness of CZP in patients with
RA treated during routine clinical practice in
the UK and Ireland.
METHODS
Patients
Patients were aged 18 years or more, screened
negative for tuberculosis [11], and had been
prescribed CZP in line with the Summary of
Product Characteristics (SmPC) [12] and the
National Institute for Health and Care
Excellence (NICE) guidelines on the use of anti-
TNF agents in RA [13]. Concomitant use of
methotrexate (MTX) and other conventional
disease-modifying antirheumatic drugs
(DMARDs) was permitted throughout this
study.
Patients were excluded if they had prior
biological DMARD exposure, had ever partici-
pated in a study of CZP, or had participated in a
study for any other investigational medication
within 30 days prior to study baseline. Patients
with any contraindications specified in the
SmPC were also excluded, including known
hypersensitivity to any components of CZP;
active tuberculosis or other severe infections;
and moderate to severe heart failure.
All patients were considered both competent
and willing to adhere to study procedures and
had agreed to an 18-month follow-up period,
regardless of any changes in treatment course
during that time. All procedures performed
were reviewed by two independent ethics com-
mittees (one for the UK and one for the
Republic of Ireland), and were compliant with
the 1964 Helsinki declaration and its later
amendments. Informed consent was obtained
from all individual participants included in the
study.
Study Design
This was a prospective, observational, post-
marketing study designed to assess long-term
clinical and patient-reported outcomes, as well
as changes in healthcare resource utilization, in
patients with RA receiving CZP during routine
clinical practice.
This study was conducted at 22 sites: 21 in
the UK and one in the Republic of Ireland. Due
to the non-interventional nature of this study,
visits were not planned in the protocol, but
were scheduled in line with routine clinical
practice. As such, data were collected at weeks 4
(± 1 week), 8 (± 1 week), 12 (± 2 weeks), 26
(± 2 weeks), 52 (± 2 weeks), 78 (± 2 weeks), and
88 (± 1 week). Patient enrollment and follow-
up took place between July 2011 and December
2014. The decision to initiate treatment with
CZP was made entirely at the discretion of the
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treating physician and was not influenced by
the study protocol. Dosing decisions were also
made by the physician in line with the SmPC
[12].
Patients prescribed CZP were assessed and
followed up as per clinical practice. Measures of
effectiveness assessed through questionnaires or
interviews were completed either at standard
visits to the clinic or via telephone contact by
the research nurse. All patients who had been
prescribed and taken at least one dose of CZP
were followed up by the clinician for up to
88 weeks, regardless of any changes to their
treatment regimen, unless they withdrew con-
sent or were lost to follow-up.
Study Procedures and Evaluations
The primary effectiveness variable was 28-joint
Disease Activity Score calculated with erythro-
cyte sedimentation rate (DAS28[ESR]) response
at week 78, summarized by week 12 response
group. DAS28(ESR) response was defined as a
reduction from baseline by at least 1.2 points
[14]. Subgroup analyses were performed to
investigate the impact of age (less than 65 or at
least 65 years), gender, rheumatoid factor (RF)
status, and anti-citrullinated protein antibody
(ACPA) status, on DAS28(ESR) response.
Secondary effectiveness variables included
change from baseline in DAS28(ESR), Health
Assessment Questionnaire-Disability Index
(HAQ-DI), and Rheumatoid Arthritis Disease
Activity Index (RADAI) scores at week 78, as
well as European League Against Rheumatism
(EULAR) response [15] at week 78.
Other effectiveness variables included chan-
ges in workplace and household productivity
[assessed using the validated Work Productivity
Survey (WPS) [16]] and patient quality of life
[assessed using the Euro Quality of Life with five
dimensions and three levels (EQ-5D-3L) ques-
tionnaire]. Patients’ level of satisfaction with
their current symptom state was assessed at
each visit using the Patient Acceptable Symp-
tomatic State (PASS) tool, in which patients
were asked to rate their current state by
answering the following question with a ‘‘Yes/
No’’ response: ‘‘Considering the full range of
activities you engage in as part of your normal
everyday life, your level of pain, and your level
of disability, if you were to remain in your
present condition for the next few months,
would you consider your current health state
satisfactory?’’ [17]. Healthcare resource utiliza-
tion data were collected at each clinic visit,
including the number and length of hospital-
izations, and the number of concurrent medical
procedures not foreseen in the study protocol.
To ensure complete safety data collection, all
adverse drug reactions (ADRs) occurring during
the study (including those that recurred or
worsened after the initial visit) were reported
directly in a safety database. Adverse events
were classified as ADRs when a causal relation-
ship between the product and the occurrence
was suspected by the reviewing healthcare pro-
fessional. Signs or symptoms of RA were only
recorded as ADRs if they changed considerably
in nature or if they increased in frequency and/
or intensity in a clinically significant manner,
compared to the patient’s clinical history or
their clinical profile at baseline. An ADR was
followed until it resolved, had stable sequelae,
was determined by the treating physician to no
longer be clinically significant, or the patient
was lost to follow-up.
Adverse events considered by the investiga-
tor to be unrelated to CZP were not collected for
this study, with the exception of adverse events
of interest.
Safety data were summarized for the safety
set (SS; all patients who received at least one
dose of CZP) and effectiveness data for the full
analysis set (FAS; all patients in the SS who had
valid DAS28[ESR] values at baseline and at week
12).
Statistical Analysis
The optimal sample size for this study was cal-
culated using a two-sided chi-squared test.
Based on an analysis of DAS28(ESR) response
data from the RAPID 1 study [18], the sample
size required to detect a 30% difference in week
78 DAS28(ESR) response between week 12
responders and non-responders was estimated
at N = 149, with a = 0.05 and 90% power.
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A dropout rate of 20% at week 12 was
anticipated, requiring a total of 187 patients to
be recruited. However, an interim analysis at
week 12 revealed a dropout rate of 5.3%, based
on 136 enrolled patients. As such, enrollment
was ceased after 149 patients. This resulted in a
loss of power of 5%. All variables were analyzed
in an exploratory manner using descriptive
statistics.
Categorical variables were summarized as the
frequency of response versus non-response
(with 95% confidence intervals [CI] for the pri-
mary effectiveness variable), and continuous
variables as the mean and standard deviation
(SD). Missing data were imputed using non-re-
sponder imputation (NRI) for categorical vari-
ables and last observation carried forward
(LOCF) for continuous variables.
RESULTS
Patient Disposition and Baseline
Characteristics
A total of 149 patients were enrolled in the
study, of whom 147 (98.7%) formed the SS and
111 (74.5%) the FAS. Most enrolled patients
(68.5%) followed the study to completion
(Fig. 1).
In the SS, most patients were female (68.7%)
and the mean (SD) age of participants was 55.6
(11.9) years. About three quarters (75.5%) of the
SS were aged less than 65 years and the majority
of patients (70.1%) were undergoing concomi-
tant treatment with MTX (Table 1). In the FAS,
most patients had high (73.9%) or moderate
(23.4%) disease activity at baseline, as measured
by DAS28(ESR) (Table 1).
Effectiveness
DAS28(ESR) Response Rates at Week 78
by Week 12 Responder Status
At week 12, 80 patients (72.1%) were
DAS28(ESR) responders and 31 (27.9%) were
non-responders. These data were used to divide
patients into two groups—week 12 responders
and week 12 non-responders—which formed
the basis for all subsequent effectiveness
analyses.
At week 78, a greater proportion of week 12
responders [43.8%, n = 35 (95% CI 32.7, 55.3)]
than non-responders [22.6%, n = 7 (9.6, 41.1)]
had a DAS28(ESR) response (Fig. 2). Subgroup
analyses suggested that this trend was consis-
tent between genders: among men, week 78
response rate was 50.0% (n = 12) in week 12
responders and 0% in non-responders, while in
women, it was 41.1% (n = 23) and 33.3%
(n = 7), respectively. Analysis by age group
indicated a similar pattern: among patients
aged less than 65 years, week 78 response rate
was 40.0% (n = 24) in week 12 responders and
26.1% (n = 6) in non-responders, while in those
aged 65 years or more, it was 55.0% (n = 11) and
12.5% (n = 1), respectively.
Similar trends were evident upon subgroup
analysis by RF status and ACPA presence. For
example, in RF-positive patients, week 78
response was 48.9% (n = 22) in week 12
Fig. 1 Patient disposition. Percentages are based on the
number of patients enrolled. A total of 60 patients (40.3%)
discontinued from CZP during the course of this study [6
(10.0%) due to intolerance, 39 (65.0%) due to lack of
efficacy, and 15 (25.0%) for other reasons]. The safety set
comprised all patients who received at least one dose of
CZP. The full analysis set comprised all patients who
received at least one dose of CZP and had valid
DAS28(ESR) values at baseline and at week 12
(± 2 weeks)
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responders and 11.1% (n = 2) in week 12 non-
responders, while in RF-negative patients, the
proportions were 41.2% (n = 7) and 30.0%
(n = 3), respectively (Supplementary Fig. 1).
Similarly, in ACPA-positive patients, the week
78 response rate was 33.3% (n = 9) in week 12
responders and 18.2% (n = 2) in week 12 non-
responders, while in ACPA-negative patients, it
was 42.1% (n = 8) and 20.0% (n = 2), respec-
tively (Supplementary Fig. 1).
Secondary Effectiveness Outcomes
On average, the mean change from baseline in
DAS28(ESR), HAQ-DI, and RADAI scores was
greater among week 12 responders than non-
responders, across all relevant time points
(Fig. 3).
Similarly, a greater proportion of week 12
responders met the criteria for a ‘‘good’’ EULAR
Table 1 Baseline demographics and disease characteristics
Characteristic SS (n = 147)
Age (years), mean (SD) 55.6 (11.9)
Age\ 65 years, n (%) 111 (75.5)
Age C 65 years, n (%) 36 (24.5)
Female, n (%) 101 (68.7)
RF positive, n (%)a 69 (65.1)
ACPA positive, n (%)a 42 (53.8)
Concomitant medications, n (%) SS (n = 147)
Specific antirheumatic agents 107 (72.8)
Methotrexate 103 (70.1)
Non-specific anti-inflammatory and
antirheumatic agents
46 (31.3)
Naproxen 12 (8.2)
Ibuprofen 9 (6.1)
Diclofenac 8 (5.4)
Non-opioid analgesics and antipyretics 25 (17.0)
Paracetamol 24 (16.3)
Antiparasitic products, insecticide and
repellent
52 (35.4)
Antimalarials 52 (35.4)
Hydroxychloroquine 49 (33.3)
Alimentary tract and metabolic agents 49 (33.3)
Sulfasalazine 44 (29.9)
Drugs for peptic ulcer and
gastroesophageal reflux
8 (5.4)
Systemic hormonal preparations
(excluding sex hormones)
36 (24.5)
Corticosteroids 35 (23.8)
Prednisolone 29 (19.7)
Methylprednisolone acetate 9 (6.1)
Triamcinolone 1 (0.7)
Triamcinolone acetonide 1 (0.7)
Antineoplastic and immunomodulating
agents
17 (11.6)
Leflunomide 16 (10.9)
Table 1 continued
Cardiovascular system agents 8 (5.4)
Disease characteristics FAS (n = 111)
DAS28(ESR) score at baseline, mean
(SD)
5.7 (1.1)
Baseline disease activity, based on
DAS28(ESR) score, n (%)
Remission (\ 2.6) 1 (0.9)
Low disease activity (2.6 to B 3.2) 2 (1.8)
Moderate disease activity ([ 3.2
to B 5.1)
26 (23.4)
High disease activity ([ 5.1) 82 (73.9)
HAQ-DI score at baseline, mean (SD) 1.7 (0.7)
RADAI score at baseline, mean (SD) 5.8 (1.6)
ACPA anti-citrullinated protein antibody, DAS28(ESR)
28-joint count disease activity score, calculated with ery-
throcyte sedimentation rate, FAS full analysis set, HAQ-DI
health assessment questionnaire-disability index, RADAI
rheumatoid arthritis disease activity index, RF rheumatoid
factor, SS safety set
a Proportions of the total number of patients who
underwent the respective tests (RF test, n = 106; ACPA
test, n = 78)
1430 Adv Ther (2018) 35:1426–1437
response at week 78 [41.3% (n = 33), compared
to 16.1% (n = 5) of non-responders], while a
greater proportion of week 12 non-responders
failed to meet the EULAR response criteria
[45.2% (n = 14), compared to 18.8% (n = 15) of
responders]. The proportions of week 12
responders and non-responders who met the
criteria for a ‘‘moderate’’ EULAR response were
approximately equal (Fig. 4).
Other Effectiveness Outcomes
The mean length of hospitalization during the
study was comparable between week 12
responders (3.13 days) and non-responders
(2.33 days), although the mean number of
concomitant medical procedures was greater
among non-responders (5.0 versus 1.0) (Sup-
plementary Table 1). Overall, there was little
change in employment status in either group,
and improvements in workplace and household
productivity were comparable (Supplementary
Tables 2 and 3).
At baseline, the PASS response was ‘‘No’’
(indicating an unacceptable symptom state,
from the patient’s perspective) for 91.0%
(n = 101) of patients, and ‘‘Yes’’ for 9.0%
(n = 10) of patients. By week 12, however, more
than half of patients (55.9%, n = 62) indicated
satisfaction with their present symptom state.
In each subsequent visit, the majority of week
12 responders had an acceptable PASS response.
Fig. 2 DAS28(ESR) response at week 78 by week 12
DAS28(ESR) responder status. Full analysis set (n = 111).
NRI imputation. 95% confidence intervals are reported in
square brackets. DAS28(ESR) 28-joint count disease
activity score, calculated with erythrocyte sedimentation
rate; NRI non-responder imputation
Fig. 3 Mean change from baseline in a DAS28(ESR),
b HAQ-DI, and c RADAI scores by week 12
DAS28(ESR) responder status. Graphs present observed
values for the full analysis set (n = 111), although patient
numbers vary between measures and across time points.
Error bars correspond to the standard deviation.
DAS28(ESR) 28-joint count disease activity score, calcu-
lated with erythrocyte sedimentation rate; HAQ-DI health
assessment questionnaire-disability index; RADAI rheuma-
toid arthritis disease activity index
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Moreover, the proportion of week 12 responders
with an acceptable PASS response consistently
exceeded that of non-responders (Supplemen-
tary Table 4).
The mean overall EQ-5D score improved
from 49.38 at baseline to 60.63 at week 12
(mean change from baseline 11.68) and
remained fairly consistent through to week 78.
Among week 12 responders, the greatest mean
change from baseline was at week 12 (15.10)
and was comparable at week 78 (13.45). By
contrast, week 12 non-responders reported little
change from baseline in EQ-5D score at weeks
12 and 26 (2.92 and 3.08, respectively), with an
increase at week 52 (10.96) that declined again
by week 78 (6.72) (Supplementary Table 5).
Safety
The median duration of exposure to CZP in this
study was 606.5 days (range 70–786 days).
Overall, nine patients (6.1%) experienced 13
ADRs (Table 2).
Two cases of pulmonary tuberculosis were
reported in this study. One was in a 52-year-old
man, who developed tuberculosis approxi-
mately 26 months after initiation of CZP. The
patient was considered negative for tuberculosis
at screening [11]. The event resolved following
6 months’ treatment with rifampicin, isoniazid,
ethambutol, and pyridoxine. CZP was then
restarted, and the patient completed the study.
The reporting physician considered the event to
be related to CZP. No further information was
available regarding the patient’s medical his-
tory, prior tuberculosis status, or the medical
testing, evaluation, or treatment of his tuber-
culosis, and there was insufficient documenta-
tion to confirm that the pathogen was
Mycobacterium tuberculosis.
The second case was in a 59-year-old woman,
who had a medical history notable for RA and
hepatic steatosis, and developed pulmonary
tuberculosis approximately 12 months after
CZP initiation. The patient was started on Rifi-
nah (rifampicin/isoniazid), pyrazinamide,
ethambutol, and pyridoxine for 2 months, and
then reduced to Rifinah and pyridoxine for
4 months. The tuberculosis was considered
resolved approximately 7 months after diagno-
sis and starting treatment, and the patient
restarted on CZP. The reporting physician con-
sidered the event to be related to CZP. No fur-
ther information was available regarding the
patient’s prior tuberculosis status.
There was also one case of cellulitis, which
was considered related to CZP and led to treat-
ment discontinuation, and one of bladder can-
cer, for which causality was not known. No
deaths were reported during this study.
DISCUSSION
Rheumatoid arthritis is a chronic, disabling
condition with a considerable impact on quality
Fig. 4 EULAR response at week 78 by week 12
DAS28(ESR) responder status. Full analysis set
(n = 111). LOCF imputation for week 12 DAS28(ESR)
values. DAS28(ESR) 28-joint count disease activity score,
calculated with erythrocyte sedimentation rate; EULAR
European League Against Rheumatism; LOCF last obser-
vation carried forward
Table 2 Adverse drug reactions
Category n (%) [# of events]
ADRs 9 (6.1) [13]
Serious ADRs 9 (6.1) [10]
AEs of interest 4 (2.7) [4]
Discontinuations due to ADRs 1 (0.7) [1]
Safety set (n = 147)
ADR adverse drug reaction, AE adverse event
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of life [2, 19, 20] and a substantial economic
burden [21–24]. CZP has proven to be an effi-
cacious option for the treatment of RA in
numerous clinical studies, with an accept-
able safety profile [3–7]. However, despite the
prevalence [25–27] and economic burden
[28, 29] of this disease in the UK and Ireland,
there are limited real-world data describing the
clinical response to CZP in these countries.
In this non-interventional study, we fol-
lowed adult patients with RA receiving CZP
during routine clinical practice in the UK and
Ireland. Our findings revealed that this popu-
lation responds to treatment with CZP in a
similar manner to patients enrolled in the
RAPID 1 and 2 clinical trials [6, 7], in which a
clinical response to CZP was evident from as
early as 1 week [7] (in the present study, clinical
improvements were observed at 4 weeks, the
earliest available time point).
Moreover, we present data indicating that a
greater proportion of week 12 DAS28(ESR)
responders (compared to week 12 non-respon-
ders) have a DAS28(ESR) response at week 78.
These findings were consistent when subgroup
analyses were performed by gender, age, RF
status, and ACPA presence, although patient
numbers were low in some groups, precluding
any definite conclusions based on these com-
parisons. A similar proportion of week 12
responders met the criteria for EULAR response
at week 78, which incorporates both current
DAS28(ESR) score and change from baseline,
and thus provides a more stringent measure of
effectiveness over time. Collectively, these data
suggest that early response to CZP may be
indicative of future response, at least to
78 weeks. This builds on observations from
randomized controlled trials: for example, a
post hoc analysis of the RAPID 1 trial revealed
that attainment of clinical response to CZP at
week 12 was associated with better clinical and
radiographic outcomes at week 52, compared to
week 12 non-responders [30].
The observed improvements in clinical
measures were closely reflected by changes in
patients’ self-reported disease activity. The
RADAI is a self-administered questionnaire that
combines five items into a single index and has
been validated for use in RA [31]. Improvements
in the RADAI were generally evident through to
week 78 and again these improvements were
more pronounced among week 12 responders.
Although a more recent tool—the RADAI-5—
has since been developed to enhance reliability,
a high degree of correlation has been noted
between the two instruments [32], suggesting
that our data remain strongly indicative of self-
reported disease activity over time.
Among the other self-reported measures of
effectiveness used in this study was the PASS,
which allows patients to express their satisfac-
tion with their current symptom state (or lack
thereof) through a simple ‘‘Yes/No’’ response
[17]. Although the PASS is not widely used in RA
studies, it is a rapid, patient-reported, and easily
comprehensible tool that has previously been
shown to discriminate patients with RA [33]
and systemic lupus erythematosus [34] on the
basis of disease activity. While the RADAI shares
some of these characteristics (ease of use, self-
administration), it requires patient responses to
multiple items and thus may be biased by
missing data. The RADAI may also be more
difficult to interpret, given that it represents a
summation of several measures in a single index
[31]. These shortcomings arguably make the
PASS a more valuable instrument for use in
clinical trials, although issues pertaining to
cross-cultural validity, as well as the discordance
between PASS response and disease activity [35],
should be considered. In the present study, a
positive PASS response appeared to correspond
to week 12 responder status: a greater propor-
tion of those who responded to CZP treatment
at week 12 reported satisfaction with their
symptoms at subsequent time points. This may
be a first step towards indicating the utility of
the PASS as a surrogate marker for RA clinical
trials; however, extensive comparisons with
conventional datasets will be necessary to sub-
stantiate this finding.
Since all participants had been prescribed
CZP by their treating physician, this study was
limited by the absence of a control group, and it
is possible that the open-label nature of the
study introduced some bias towards the
reporting of effectiveness. Nevertheless, the
findings presented in this report demonstrate
the long-term effectiveness of CZP for the
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treatment of RA in a real-world setting. This is
consistent with data from various open-label
extension studies, in which CZP was shown to
be effective and to have an acceptable safety
profile over several years of treatment in
patients with RA [18, 36, 37].
The results of this study position CZP
alongside a panel of anti-TNF agents that have
demonstrated real-world effectiveness in the
treatment of RA [38–40]. Moreover, the safety
outcomes reported for this patient population
were in line with the known safety profile for
anti-TNF inhibitors [41–44], and no new safety
signals emerged when administering CZP in a
real-world setting [45]. The ADR rate observed
in this study was lower than that seen in many
other studies, which may be attributable to its
non-interventional nature (comparatively low
rates of ADRs are an established phenomenon
in non-interventional studies [46]). In addition,
it is important to note that adverse events
considered unrelated to CZP treatment were not
recorded in this study, which may have con-
tributed to the low reported rate.
CONCLUSIONS
The data presented in this report indicate that
CZP is an effective treatment for adult patients
with RA in a clinical setting in the UK and Ire-
land. Thus, CZP may form part of treat-to-target
strategy for this patient population, both
improving patients’ quality of life and reducing
the economic burden of disease in these
countries.
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